Transfer of the active form of transforming growth factor-β1 gene to newborn rat lung induces changes consistent with bronchopulmonary dysplasia

被引:143
作者
Gauldie, J
Galt, T
Bonniaud, P
Robbins, C
Kelly, M
Warburton, D
机构
[1] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada
[2] Ctr Hosp Univ Bocage, Serv Pneumol & Reanimat Resp, Dijon, France
[3] Univ Bourgogne, Dijon, France
[4] Univ So Calif, Keck Sch Med, Childrens Hosp, Los Angeles Res Inst,Dev Biol Program, Los Angeles, CA USA
关键词
D O I
10.1016/S0002-9440(10)63612-7
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Bronchopulmonary dysplasia is a chronic lung disease of premature human infancy that shows pathological features comprising varying sized areas of interstitial fibrosis in association with distorted large alveolar spaces. We have previously shown that transfer of active transforming growth factor (TGF)-beta1 (AdTGFbeta1(223/225)) genes by adenovirus vector to embryonic lungs results in inhibition of branching morphogenesis and primitive peripheral lung development, whereas transfer to adult lungs results in progressive interstitial fibrosis. Herein we show that transfer of TGF-beta1 to newborn rat pups results in patchy areas of interstitial fibrosis developing throughout a period of 28 days after transfer. These areas of fibrosis appear alongside areas of enlarged alveolar spaces similar to the prealveoli seen at birth, suggesting that postnatal lung development and alveolarization has been inhibited. In rats treated with AdTGFbeta1(223/225), enlarged alveolar spaces were evident by day 21, and by 28 days, the mean alveolar cord length was nearly twice that in control vector or untreated rats. Hydroxyproline measurements confirmed the presence of fibrosis. These data suggest that overexpression of TGF-beta1 during the critical period of postnatal rat lung alveolarization gives rise to pathological, biochemical, and morphological changes consistent with those seen in human bronchopulmonary dysplasia, thus inferring a pathogenic role for TGF-beta in this disorder.
引用
收藏
页码:2575 / 2584
页数:10
相关论文
共 35 条
[21]   Transfer of tumor necrosis factor-α to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-β1 and myofibroblasts [J].
Sime, PJ ;
Marr, RA ;
Gauldie, D ;
Xing, Z ;
Hewlett, BR ;
Graham, FL ;
Gauldie, J .
AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (03) :825-832
[22]   Adenovector-mediated gene transfer of active transforming growth factor-beta 1 induces prolonged severe fibrosis in rat lung [J].
Sime, PJ ;
Xing, Z ;
Graham, FL ;
Csaky, KG ;
Gauldie, J .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (04) :768-776
[23]   Fibronectin expression in bronchopulmonary dysplasia [J].
Sinkin, RA ;
Roberts, M ;
LoMonaco, MB ;
Sanders, RJ ;
Metlay, LA .
PEDIATRIC AND DEVELOPMENTAL PATHOLOGY, 1998, 1 (06) :494-502
[24]   INTRATRACHEAL GENE DELIVERY WITH ADENOVIRAL VECTOR INDUCES ELEVATED SYSTEMIC IGG AND MUCOSAL IGA ANTIBODIES TO ADENOVIRUS AND BETA-GALACTOSIDASE [J].
VANGINKEL, FW ;
LIU, CG ;
SIMECKA, JW ;
DONG, JY ;
GREENWAY, T ;
FRIZZELL, RA ;
KIYONO, H ;
MCGHEE, JR ;
PASCUAL, DW .
HUMAN GENE THERAPY, 1995, 6 (07) :895-903
[25]  
VINCENCIO AG, 2003, AM J RESP CRIT CARE, V167, pA594
[26]   The molecular basis of lung morphogenesis [J].
Warburton, D ;
Schwarz, M ;
Tefft, D ;
Flores-Delgado, G ;
Anderson, KD ;
Cardoso, WV .
MECHANISMS OF DEVELOPMENT, 2000, 92 (01) :55-81
[28]  
Xing Z, 1997, AM J PATHOL, V150, P59
[29]   Transfer of granulocyte-macrophage colony-stimulating factor gene to rat lung induces eosinophilia, monocytosis, and fibrotic reactions [J].
Xing, Z ;
Ohkawara, Y ;
Jordana, M ;
Graham, FL ;
Gauldie, J .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (04) :1102-1110
[30]   Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia [J].
Yoon, BH ;
Romero, R ;
Jun, JK ;
Park, KH ;
Park, JD ;
Ghezzi, F ;
Kim, BI .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 177 (04) :825-830